B cells imprint adoptively transferred CD8
B-lymphocytes
T-lymphocytes
adoptive
immunotherapy
lymphocytes
melanoma
tumor-infiltrating
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
29
11
2021
entrez:
12
1
2022
pubmed:
13
1
2022
medline:
17
3
2022
Statut:
ppublish
Résumé
Adoptive T cell transfer (ACT) therapy improves outcomes in patients with advanced malignancies, yet many individuals relapse due to the infusion of T cells with poor function or persistence. Toll-like receptor (TLR) agonists can invigorate antitumor T cell responses when administered directly to patients, but these responses often coincide with toxicities. We posited that TLR agonists could be repurposed ex vivo to condition T cells with remarkable potency in vivo, circumventing TLR-related toxicity. In this study we investigated how tumor-specific murine CD8 Herein we reveal a new way to reverse the tolerant state of adoptively transferred CD8 Our results demonstrate a novel way to use TLR agonists to improve immunotherapy and reveal a vital role for B cells in the generation of potent CD8
Sections du résumé
BACKGROUND
Adoptive T cell transfer (ACT) therapy improves outcomes in patients with advanced malignancies, yet many individuals relapse due to the infusion of T cells with poor function or persistence. Toll-like receptor (TLR) agonists can invigorate antitumor T cell responses when administered directly to patients, but these responses often coincide with toxicities. We posited that TLR agonists could be repurposed ex vivo to condition T cells with remarkable potency in vivo, circumventing TLR-related toxicity.
METHODS
In this study we investigated how tumor-specific murine CD8
RESULTS
Herein we reveal a new way to reverse the tolerant state of adoptively transferred CD8
CONCLUSIONS
Our results demonstrate a novel way to use TLR agonists to improve immunotherapy and reveal a vital role for B cells in the generation of potent CD8
Identifiants
pubmed: 35017148
pii: jitc-2021-003078
doi: 10.1136/jitc-2021-003078
pmc: PMC8753437
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : S10 OD025126
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA243307
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208514
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA175061
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA138313
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA232646
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA138292
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA233168
Pays : United States
Organisme : NIDCR NIH HHS
ID : K08 DE026542
Pays : United States
Organisme : NIH HHS
ID : S10 OD010731
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001450
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No, there are no competing interests.
Références
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52
pubmed: 17517626
Cancer Immunol Res. 2017 Oct;5(10):898-907
pubmed: 28848053
Ann Oncol. 2017 Aug 1;28(8):1756-1766
pubmed: 28444111
J Clin Invest. 2005 Mar;115(3):739-46
pubmed: 15696196
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Cancer Res. 2011 Aug 15;71(16):5445-54
pubmed: 21708958
Cancer Discov. 2018 Oct;8(10):1258-1269
pubmed: 30154192
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
Sci Transl Med. 2015 Oct 28;7(311):311ra170
pubmed: 26511507
Invest New Drugs. 2014 Dec;32(6):1278-84
pubmed: 24894651
J Exp Med. 2005 Oct 3;202(7):907-12
pubmed: 16203864
Cancer Immunol Immunother. 2011 May;60(5):671-83
pubmed: 21327636
J Clin Invest. 2007 May;117(5):1184-94
pubmed: 17476348
J Immunol. 2015 Feb 15;194(4):1737-47
pubmed: 25576595
J Immunother Cancer. 2016 Feb 16;4:6
pubmed: 26885368
J Am Coll Surg. 2012 Apr;214(4):700-7; discussion 707-8
pubmed: 22360982
Front Immunol. 2017 Sep 29;8:1221
pubmed: 29033940
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cell Mol Immunol. 2009 Jun;6(3):199-205
pubmed: 19567203
Immunity. 2012 Jan 27;36(1):68-78
pubmed: 22206904
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cell Rep. 2016 Feb 9;14(5):1218-1231
pubmed: 26832412
Front Immunol. 2019 Apr 02;10:604
pubmed: 31001249
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
Blood. 2012 Jan 12;119(2):355-63
pubmed: 22045986
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Science. 2020 Dec 11;370(6522):1328-1334
pubmed: 33303615
J Immunol. 1980 Aug;125(2):711-4
pubmed: 6156213
Int J Cancer. 2010 Feb 15;126(4):909-18
pubmed: 19728336
JCI Insight. 2019 May 16;4(10):
pubmed: 31092734
Sci Transl Med. 2010 Oct 27;2(55):55ra78
pubmed: 20980695
J Leukoc Biol. 2007 Apr;81(4):1075-85
pubmed: 17227820
Methods Mol Biol. 2018;1711:133-148
pubmed: 29344888
J Clin Invest. 2007 Aug;117(8):2197-204
pubmed: 17657310
Eur J Immunol. 2007 Nov;37(11):3040-53
pubmed: 17918201
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Cell Rep. 2012 Sep 27;2(3):628-39
pubmed: 22959433
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14336-41
pubmed: 23940348
Immunobiology. 2017 Jan;222(1):89-100
pubmed: 27349597
Nature. 2009 Jul 2;460(7251):103-7
pubmed: 19494812
J Exp Med. 2003 Aug 18;198(4):569-80
pubmed: 12925674
Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89
pubmed: 21643519
Cancer Discov. 2018 Oct;8(10):1250-1257
pubmed: 30154193
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Front Immunol. 2019 Jun 06;10:925
pubmed: 31244820
Cancer Discov. 2021 Aug;11(8):1996-2013
pubmed: 33707233
J Clin Oncol. 2010 Oct 1;28(28):4324-32
pubmed: 20697067
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Cancer Res. 2018 Jan 1;78(1):115-128
pubmed: 29066514
J Immunol. 2005 Mar 1;174(5):2591-601
pubmed: 15728465
Clin Transl Immunology. 2016 May 20;5(5):e85
pubmed: 27350884
Cancer. 2009 Sep 1;115(17):3944-54
pubmed: 19536884
PLoS Pathog. 2015 Oct 20;11(10):e1005177
pubmed: 26485519